Breaks Categories: Analyst Alerts

FridayDec 08, 2017 9:12 am

NetworkNewsBreaks – SeeThruEquity Updates Coverage on PotNetwork Holding, Inc. (POTN)

SeeThruEquity recently issued a company update and price target of $0.40 on shares of PotNetwork Holding, Inc.’s (OTC: POTN) stock. SeeThruEquity increased the price target for PotNetwork based on encouraging results since it initiated coverage of the holding company, such as top line growth and reduction in shares outstanding. New product launches, aggressive marketing initiatives and entry into to new markets were noted by the analyst as upcoming catalysts for the company. To view the full press release, visit http://nnw.fm/rFU2b About PotNetwork Holding, Inc. PotNetwork Holding, Inc. (OTC: POTN) is a publicly traded company that acts as a holding company…

Continue Reading

ThursdayOct 19, 2017 11:27 am

NetworkNewsBreaks – Mizuho Securities Reiterates ‘Buy’ Rating on ViewRay, Inc. (NASDAQ: VRAY)

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $12 on shares of ViewRay, Inc.’s (NASDAQ: VRAY) stock following a conference call with a medical physicist hosted by Mizuho on October 17. Highlights from the discussion included numerous key benefits associated with ViewRay’s MRI-Cobalt and MRI-LINAC. Among other highlights, the consultant noted that the most important achievement of MRIdian is its ability to improve treatment effectiveness due to greater visualization of patients’ internal anatomy compared to traditional alternatives such as X-Ray technology. Specifically, MRI-LINAC delivers substantial improvements in soft-tissue tracking and protection of sensitive surrounding organs.…

Continue Reading

MondayOct 16, 2017 11:37 am

NetworkNewsBreaks – Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) Receives Reiterated “Buy” Rating at Mizuho Securities

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock following the FDA's Dermatologic and Ophthalmic Drug Advisory Committee vote in favor of Rhopressa. The committee’s decision regarded two key points: efficacy for reducing intraocular pressures (IOP) and efficacy outweighing safety risks. First, the committee voted 10-0 when asked if the clinical trials support Rhopressa's efficacy for reducing elevated IOP for patients with open-angle glaucoma or ocular hypertension. The second question posed to the committee asked if the identified safety risks were outweighed by the efficacy demonstrated…

Continue Reading

ThursdayOct 12, 2017 9:30 am

NetworkNewsBreaks – Mizuho Securities Issues Update, Reiterates “Buy” Rating on Aerie Pharmaceuticals, Inc. (NASDAQ: AERI)

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and price target of $70 on shares of Aerie Pharmaceuticals, Inc.’s (NASDAQ: AERI) stock following review of the Rhopressa advisory committee briefing package. The analyst noted that, upon review, they believe the FDA's stance is favorable toward Aerie’s Rhopressa. Per the briefing package, the FDA agrees with Aerie's conclusion regarding the overall efficacy of Rhopressa with once-daily dosing for the reduction of elevated intraocular pressure. The analyst noted that the FDA didn’t uncover anything concerning regarding Aeri’s safety findings. However, the FDA did suggest modifications to the proposed language used on…

Continue Reading

TuesdayOct 10, 2017 11:51 am

NetworkNewsBreaks – SeeThruEquity Issues Update on ChineseInvestors.com, Inc. (CIIX)

SeeThruEquity has updated its coverage and maintained its price target of $3.75 on shares of ChineseInvestors.com, Inc.’s (OTCQB: CIIX) stock. Among other highlights, the analyst noted the company’s recently released financial results for the full year fiscal 2017. The company reported revenue growth of 75.9% over 2016, with revenues dramatically increasing in both its investor relations and subscription services segments. The analyst also noted the company’s firm focus on the emerging cannabidiol (CBD) health products market. CIIX has high expectations for its wholly owned foreign subsidiary CBD Biotechnology Co. Ltd.’s new "CBD Magic Hemp" skin care line. CBD Biotechnology recently…

Continue Reading

ThursdayOct 05, 2017 1:24 pm

NetworkNewsBreaks – SeeThruEquity Initiates Coverage on Cemtrex, Inc. (NASDAQ: CETX)

SeeThruEquity has initiated coverage and issued a price target of $6.45 on shares of Cemtrex, Inc.’s (NASDAQ: CETX) stock. Among other highlights, the analyst noted the company’s history of healthy growth through large accretive acquisitions undertaken by management. The company’s operations are split into two market segments: Electronics Manufacturing Services (EMS) and Industrial Products and Services (IPS). The company’s core EMS enables Cemtrex to offer a full end-to-end solution for original equipment manufacturer (OEM) partners to develop and introduce new products. The analyst believes Cemtrex has been overlooked on Wall Street and extremely undervalued in the industrial manufacturing and EMS…

Continue Reading

ThursdayOct 05, 2017 11:48 am

NetworkNewsBreaks – Mizuho Securities Initiates Coverage with ‘Neutral’ Rating on FibroGen, Inc. (NASDAQ: FGEN)

Mizuho Securities USA LLC has initiated coverage with a ‘Neutral’ rating and price target of $61 on shares of FibroGen, Inc.’s (NASDAQ: FGEN) stock. Roxadustat is the company’s most advanced product candidate, currently in phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD). The analyst noted that the global collaboration deals FibroGen has in place position the company for a successful, global commercial launch of roxadustat upon NDA approval. Additionally, the analyst believes the company is nearing full valuation. For more information, visit www.fibrogen.com About FibroGen, Inc. FibroGen, Inc., headquartered in San Francisco, CA with…

Continue Reading

ThursdayOct 05, 2017 11:46 am

NetworkNewsBreaks – Akebia Therapeutics, Inc. (NASDAQ: AKBA) Receives ‘Buy’ Rating from Mizuho Securities

Mizuho Securities USA LLC has initiated coverage with a ‘Buy’ rating and price target of $24 on shares of Akebia Therapeutics, Inc.’s (NASDAQ: AKBA) stock. The company’s lead product candidate, vadadustat, is currently in phase 3 trials for the treatment of anemia related to chronic kidney disease. Among other highlights, the analyst noted Akebia’s established partnerships with several important players in the renal market in preparation for commercialization of vadadustat. Mizuho analysts believe that Akebia is attractively valued considering the company’s lead product candidate, vadadustat, and the global collaboration deals in place. For more information, visit www.akebia.com About Akebia Therapeutics…

Continue Reading

WednesdayOct 04, 2017 11:48 am

NetworkNewsBreaks – SeeThruEquity Updates Coverage on Apricus Biosciences, Inc. (NASDAQ: APRI)

SeeThruEquity issued a company update and price target of $4.30 on shares of Apricus Biosciences, Inc.’s (NASDAQ: APRI) stock. The analyst noted that the company has several upcoming catalysts, including the FDA decision for its Vitaros™ New Drug Application (NDA) resubmission. The company has already received its PDUFA date, which is February 17, 2018. If approved, Vitaros™ could be commercialized in the multi-billion-dollar erectile dysfunction (ED) market by the end of 2018. For more information, visit www.Apricusbio.com About Apricus Biosciences, Inc. Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product…

Continue Reading

TuesdayOct 03, 2017 3:24 pm

NetworkNewsBreaks – Mizuho Securities Reiterates ‘Buy’ Rating, Raises PT on Zogenix, Inc. (NASDAQ: ZGNX)

Mizuho Securities USA LLC has reiterated its ‘Buy’ rating and raised its price target from $28.00 to $51.00 on shares of Zogenix, Inc.’s (NASDAQ: ZGNX) stock. The report follows the company’s release of positive topline data for its pivotal phase 3 trial of ZX008 in Dravet Syndrome - Study 1. The study reached its primary endpoint, representing that 0.8 mg/kg/day of ZX008 as an adjunctive therapy is greater than a placebo in reducing mean monthly convulsive seizure frequency. The results also validate ZX008s mechanism of action involving Sig-1R receptor. The analyst noted that the efficacy results are better than expected,…

Continue Reading